Clinical impact and cost-effectiveness of antiretroviral therapy in India: Starting criteria and second-line therapy

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Freedberg, Kenneth A ^a,b,c,d   Kumarasamy, Nagalingeswaran ^e   Losina, Elena ^a,d   Cecelia, Anitha J ^e   Scott, Callie A ^a   Divi, Nomita ^a   Flanigan, Timothy P ^f   Lu, Zhigang ^a   Weinstein, Milton C ^c   Wang, Bingxia ^a   Ganesh, Aylur K ^e   Bender, Melissa A ^a,b,c   Mayer, Kenneth H ^f   Walensky, Rochelle P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^f BROWN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; India

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LIFE EXPECTANCY; MONOTHERAPY; PARAMETER; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INDIA; LIFE EXPECTANCY; MALE; MODELS, ECONOMETRIC; TREATMENT OUTCOME;

EID: 34447326983     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279714.60935.a2     Document Type: Article

References (45)

1. WHO. Summary country profile for HIV/AIDS treatment scale-up: India. http://www.who.int/hiv/HIVCP_IND.pdf. Accessed: 30 March 2007.
2. UNAIDS/WHO. AIDS epidemic update: special report on HIV/AIDS: December 2006. http://www.unaids.org/en/HIV_data/epi2006/default.asp. Accessed: 30 March 2007.
3. Kumarasamy N, Solomon S, Chaguturu SK, Cecelia AJ, Vallabhaneni S, Flanigan TP, Mayer KH. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005; 41:1525-1528.
4. Steinbrook R. HIV in India - the challenges ahead. N Engl J Med 2007; 356:1197-1201.
5. National AIDS Control Organization, Ministry of Health and Family Welfare, India Go. National guidelines for implementation of antiretroviral therapy (ART). http://www.nacoonline.org/guidelines/ART_Guidelines.pdf. Accessed: 30 March 2007.
6. Gupta SB, Pujari SN, Joshi SR, Patel AK. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. J Assoc Physicians India 2006; 54:57-74.
7. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. http://www.who.int/HIV/pub/guidelines/arvguidelines2006. pdf. Accessed: 30 March 2007.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
9. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831.
10. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
11. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
12. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 2003; 158:687-694.
13. Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf L, Messou E, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antiviral Therapy (in press).
14. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38:174-179.
15. Young B, Fischl MA, Wilson HM, Finn TS, Jensen EH, DiNubile MJ, Zeldin RK. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002; 31:478-482.
16. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003; 36:79-85.
17. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. http://www.who.int/HIV/pub/guidelines/ctxguidelines.pdf. Accessed: 9 March 2007.
18. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, Weinstein MC, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-1308.
19. Walensky RP, Weinstein MC, Yazdanpanah Y, Losina E, Mercincavage LM, Toure SM, et al. HIV drug resistance surveillance for prioritizing treatment in resource limited settings. AIDS 2007; 21:973-982.
20. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, Balakrishnan P, Flanigan TP. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574-1576.
21. Cecelia AJ, Christybai P, Anand S, Jayakumar K, Gurunathan T, Vidya P, et al. Usefulness of an observational database to assess antiretroviral treatment trends in India. Natl Med J India 2006; 19:14-17.
22. Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Information Service; 1995.
23. Wang B, Kumarasamy N, Divi N, Cecilia AJ, Mayer KH, Lu Z, et al. Incidence of opportunistic infections (OIs) within specific CD4 strata in HIV-infected patients in Southern India [abstract WePe0279.]. XVI International AIDS Conference; 16 August 2006; Toronto, Canada.
24. Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR 3rd, et al. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J 2006; 96:526-529.
25. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-1468.
26. Lopez A, Ahmad O, Guillot M, Ferguson B, Saloman J, Murray CJL, et al. In: World Mortality in 2000: Life Tables for 191, Countries. Geneva: World Health Organization; 2002.
27. Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR 3rd, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med 2002; 162:921-928.
28. Unit Costs for Components of HIV-Related Health Care 2005. Chennai, India: YRG CARE Pharmacy.
29. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-450.
30. Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, et al. Cohort profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005; 34:979-986.
31. Homan RK, Ganesh AK, Duraisamy P, Castle C, Sripriya M, Franklin B, Solomon S, et al. Economic Analyses of YRG CARE Services. Research Triangle Park: Family Health International; 2000.
32. Weinstein MC. Decision rules for incremental cost-effectiveness analysis. In: The Elgar Companion to Health Economics. Edited by Jones AM. Cheltenham: Edward Elgar Publishing Ltd; 2006. pp. 469-478.
33. WHO. The world health report 2002: reducing risks, promoting health life. http://www.who.int/whr/2002/en/whr02_en.pdf. Accessed: 19 March 2007.
34. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15:1143-1148.
35. Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, et al. Reasons formodification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41:53-58.
36. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis 2006; 33:S145-S152.
37. Over M, Heywood P, Gold J, Gupta I, Hira S, Marseille E. HIV/AIDS treatment and prevention in India: modeling the cost and consequences. http://siteresources.worldbank.org/INTINDIA/Resources/IndiaARTReport1.pdf. Accessed: 21 May 2007.
38. Ravenga A, Over M, Masaki E, et al. The economics of effective AIDS treatment: evaluating policy options for Thailand. http://siteresources. worldbank.org/INTEAPREGTOPHIVAIDS/Resources/AIDS-Treatment-effectiveness-TOC. pdf. Accessed: 21 May 2007.
39. Gupta I, Trivedi M, Kandamuthan S. Costing of the free ART programme of the Government of India. http://iegindia.org/dis_111_2006.pdf. Accessed: 21 May 2007.
40. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145:797-806.
41. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44:1115-1122.
42. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak E, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570-585.
43. Walensky RP, Wood R, Losina E, Martinson N, Weinstein MC, Mercincavage LM, et al. Waiting for ART in South Africa: deaths averted with a more aggressive scale-up [abstract 549]. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, California.
44. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed: 21 May 2007.
45. The Clinton Foundation. Antiretroviral (ARV) price list. http://www.clintonfoundation.org/pdf/chai-arv-price-list-050807.pdf. Accessed: 21 May 2007.